文献速递系统性红斑狼疮类风湿关节炎

钠-葡萄糖协同转运蛋白2(SGLT2)抑制与自身免疫

Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunity.
PubMed 文献 · Semin Arthritis Rheum · 2025-02-21

本文综述SGLT2抑制剂在自身免疫疾病中的潜在作用。DAPA-CKD试验排除了系统性红斑狼疮伴狼疮肾炎或ANCA相关肾小球肾炎患者,EMPA-KIDNEY试验将3个月内使用大剂量糖皮质激素或静脉免疫抑制作为排除标准,故此类药物在活动性自身免疫性肾病患者中尚未被系统测试。SGLT2抑制剂在体内外研究中显示对SLE、狼疮肾炎和类风湿关节炎有管理自身免疫的疗效,但需在人体中确认。

要点

  • DAPA-CKD试验排除了系统性红斑狼疮伴狼疮肾炎或ANCA相关肾小球肾炎患者。
  • EMPA-KIDNEY试验将3个月内使用大剂量糖皮质激素或静脉免疫抑制作为排除标准。
  • SGLT2抑制剂在体内外研究显示对SLE、狼疮肾炎和类风湿关节炎有管理自身免疫的疗效。

核心结论

  • SGLT2抑制剂在SLE、狼疮肾炎和类风湿关节炎中显示体内外管理自身免疫的疗效,但需在人体中确认。
  • 这些药物在活动性自身免疫性肾病患者中尚未被系统测试,且这一空白不太可能由高质量随机临床试验填补。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • DAPA-CKD试验排除了系统性红斑狼疮伴狼疮肾炎或ANCA相关肾小球肾炎患者。
  • EMPA-KIDNEY试验将3个月内使用大剂量糖皮质激素或静脉免疫抑制作为排除标准。
  • SGLT2抑制剂在体内外研究显示对SLE、狼疮肾炎和类风湿关节炎有管理自身免疫的疗效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些药物在活动性自身免疫性肾病患者中尚未被系统测试,且这一空白不太可能由高质量随机临床试验填补。
  • SGLT2抑制剂在SLE、狼疮肾炎和类风湿关节炎中的疗效需在人体中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The approval of sodium-glucose cotransporter (SGLT2) inhibitors has revolutionized the management of patients with diabetes, heart failure and especially those with chronic kidney disease (CKD). Beyond development of CKD, patients with autoimmune disorders have an increased cardiovascular morbidity and mortality. Therefore, this patient population would benefit the most from effective therapies to reduce this burden, and secondly, slowing of CKD progression to reduce the frequency of kidney failure. Patients with systemic autoimmune disorders, such as systemic lupus erythematosus with lupus nephritis or anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis were excluded from the DAPA-CKD trial, and higher doses of glucocorticoids or intravenous use of immunosuppression within 3 months were exclusion criteria of the EMPA-KIDNEY trial. Thus, these agents remain untested in patients with active autoimmune kidney diseases in a systematic way, and this gap is unlikely to be filled by high-quality randomized clinical trials. Beyond having nephro- and cardioprotective effects, SGLT2i have shown in vivo and in vitro efficacy to manage autoimmunity in SLE, LN and rheumatoid arthritis (RA). These effects need to be confirmed in humans, but might provide a further rationale for the use of these potent drugs. The safety profile is in general favourable, but "sick day rules" need to be followed in order to avoid serious side effects.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kronbichler A. Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunity. Semin Arthritis Rheum. 2025. PMID: 40016066. doi:10.1016/j.semarthrit.2025.152663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。